Covered recipient · General Payments record
RICHARD MARKOWITZ
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2019–2024
$722.00
- Reported across 18 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $525.57 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $201.67 | 6 |
| BOSTON SCIENTIFIC CORPORATION | $113.46 | 1 |
| Phathom Pharmaceuticals, Inc. | $72.26 | 3 |
| Janssen Biotech, Inc. | $59.80 | 3 |
| ABBVIE INC. | $59.74 | 2 |
| Ardelyx, Inc. | $18.64 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $31.78 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104968392 | CMS |
| ABBVIE INC. | $27.96 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104968394 | CMS |
| Ardelyx, Inc. | $18.64 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146694218 | CMS |
| Boston Scientific Corporation | $113.46 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092288079 | CMS |
| Janssen Biotech, Inc. | $20.07 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078429745 | CMS |
| Janssen Biotech, Inc. | $20.60 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078429969 | CMS |
| Janssen Biotech, Inc. | $19.13 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078429500 | CMS |
| Novo Nordisk Inc | $17.98 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096715619 | CMS |
| Novo Nordisk Inc | $13.78 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096912724 | CMS |
| Novo Nordisk Inc | $17.27 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096619670 | CMS |
| Novo Nordisk Inc | $16.03 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097481821 | CMS |
| Novo Nordisk Inc | $17.30 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096715571 | CMS |
| Novo Nordisk Inc | $119.31 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097800523 | CMS |
| Phathom Pharmaceuticals, Inc. | $28.63 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151093291 | CMS |
| Phathom Pharmaceuticals, Inc. | $24.78 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151093293 | CMS |
| Phathom Pharmaceuticals, Inc. | $18.85 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151093295 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2022, 2024
- Source files
- Dataset page · Bulk file · PY2019 , PY2022 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.